{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006996","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.628848+00:00","generated_at":"2026-05-16T11:10:17.587234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track","bullets":["Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).","Exceeded guidance and expectations for both combined and continuing operations.","SomaLogic sale to Illumina on track to close H1 2026; expects ~$550M cash post-close.","Base business on track to positive adjusted EBITDA; positioned for disciplined M&A.","Streamlined operations and improved cost structure exiting year as leaner organization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006996","json":"https://secwatch.observer/filing/0001193125-26-006996.json","markdown":"https://secwatch.observer/filing/0001193125-26-006996.md","text":"https://secwatch.observer/filing/0001193125-26-006996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/0001193125-26-006996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/lab-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:10:17.587234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}